MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors

Defining the role of mTOR in cancer

Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833

Phosphorylation of ULK1 (hATG1) by AMP-Activated Protein Kinase Connects Energy Sensing to Mitophagy

Egan, D. F., Shackelford, D. B., Mihaylova, M. M., Gelino, S., Kohnz, R. A., Mair, W., Vasquez, D. S., Joshi, A., Gwinn, D. M., Taylor, R., et al. (2011) · Science · doi:10.1126/science.1196371 · Cited by 2,600

mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt

O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC

Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.022 · Cited by 1,059

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P. K., Baselga, J., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.031 · Cited by 967

Activation of Akt and eIF4E Survival Pathways by Rapamycin-Mediated Mammalian Target of Rapamycin Inhibition

Sun, S., Rosenberg, L. M., Wang, X., Zhou, Z., Yue, P., Fu, H., & Khuri, F. R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0917 · Cited by 800

Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment

Jura, N., Endres, N., Engel, K., Deindl, S., Das, R., Lamers, M. H., Wemmer, D. E., Zhang, X., & Kuriyan, J. (2009) · Cell · doi:10.1016/j.cell.2009.04.025 · Cited by 609

Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor

Yeh, T. C., Marsh, V., Bernat, B. A., Ballard, J., Colwell, H., Evans, R. J., Parry, J., Smith, D. J., Brandhuber, B. J., Gross, S. D., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1150 · Cited by 578

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

Serra, V., Scaltriti, M., Prudkin, L., Eichhorn, P. J. A., Ibrahim, Y. H., Chandarlapaty, S., Markman, B., Rodríguez, O., Guzmán, M., Rodriguez, S., et al. (2011) · Oncogene · doi:10.1038/onc.2010.626 · Cited by 541

ACAGT-007a, an ERK MAPK Signaling Modulator, in Combination with AKT Signaling Inhibition Induces Apoptosis in KRAS Mutant Pancreatic Cancer T3M4 and MIA-Pa-Ca-2 Cells

Khandakar, G. I., Satoh, R., Takasaki, T., Fujitani, K., Tanabe, G., Sakai, K., Nishio, K., & Sugiura, R. (2022) · Cells · doi:10.3390/cells11040702 · Cited by 15

NFIB facilitates replication licensing by acting as a genome organizer

Zhang, W., Wang, Y., Liu, Y., Liu, C., Wang, Y., He, L., Cheng, X. L., Peng, Y., Xia, L., Wu, X., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40846-1 · Cited by 14

MEK/ERK and PI3K/AKT pathway inhibitors affect the transformation of myelodysplastic syndrome into acute myeloid leukemia via H3K27me3 methylases and de‑methylases

Zheng, Z., Chen, X., Zhang, Y., Ren, F., & Ma, Y. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5588 · Cited by 14

Drug sensitivity profile of minor KRAS mutations in colorectal cancer using mix culture assay: The effect of AMG‑510, a novel KRAS G12C selective inhibitor, on colon cancer cells is markedly enhanced by the combined inhibition of MEK and BCL‑XL

Kitazawa, M., Miyagawa, Y., Koyama, M., Nakamura, S., Hondo, N., Miyazaki, S., Muranaka, F., Tokumaru, S., Yamamoto, Y., Ehara, T., et al. (2021) · Molecular and Clinical Oncology · doi:10.3892/mco.2021.2310 · Cited by 15

Targeting protein arginine methyltransferase 5 sensitizes glioblastoma to trametinib

Banasavadi‐Siddegowda, Y., Namagiri, S., Otani, Y., Sur, H. P., Rivas, S. R., Bryant, J.-P., Shelbourn, A., Rock, M. B., Chowdhury, A. K., Lewis, C. T., et al. (2022) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdac095 · Cited by 14

Suppression of B-Raf(V600E) cancers by MAPK hyper-activation

Atiq, R., Hertz, R., Eldad, S., Smeir, E., & Bar‐Tana, J. (2016) · Oncotarget · doi:10.18632/oncotarget.7909 · Cited by 14

A combination of trastuzumab and BAG-1 inhibition synergistically targets HER2 positive breast cancer cells

Papadakis, E., Robson, N., Yeomans, A., Bailey, S. G., Laversin, S. A., Beers, S. A., Sayan, E., Ashton‐Key, M., Schwaiger, S., Stuppner, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7944 · Cited by 14

Cyclooxygenase-2 Influences Response to Cotargeting of MEK and CDK4/6 in a Subpopulation of Pancreatic Cancers

Maust, J. D., Frankowski-McGregor, C. L., Bankhead, A., Simeone, D. M., & Sebolt, J. S. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0082 · Cited by 12

Inhibition of ISG15 Enhances the Anti-Cancer Effect of Trametinib in Colon Cancer Cells

Zhou, S., Ren, M., Xu, H., Xia, H., Tang, Q., & Liu, M. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s226395 · Cited by 14

MicroRNA-16 Restores Sensitivity to Tyrosine Kinase Inhibitors and Outperforms MEK Inhibitors in KRAS-Mutated Non-Small Cell Lung Cancer

Fanini, F., Bandini, E., Plousiou, M., Carloni, S., Wise, P. M., Neviani, P., Murtadha, M., Foca, F., Fabbri, F., Vannini, I., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413357 · Cited by 13

Oncogenic Ras triggers hyperproliferation and impairs polarized colonic morphogenesis by autocrine ErbB3 signaling

Möller, Y., Morkel, M., Schmid, J. O., Beyes, S., Hendrick, J., Strotbek, M., Riemer, P., Schmid, S., Schmitt, L. C., Kontermann, R. E., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10658 · Cited by 16

Structure-Guided Design and Initial Studies of a Bifunctional MEK/PI3K Inhibitor (ST-168)

Dort, M. E. V., Galbán, S., Nino, C. A., Hong, H., Apfelbaum, A. A., Luker, G. D., Thurber, G. M., Atangcho, L., Besirli, C. G., & Ross, B. D. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00111 · Cited by 13

Transcriptionally inducible Pleckstrin homology-like domain, family A, member 1, attenuates ErbB receptor activity by inhibiting receptor oligomerization

Magi, S., Iwamoto, K., Yumoto, N., Hiroshima, M., Nagashima, T., Ohki, R., García-Muñoz, A., Volinsky, N., von Kriegsheim, A., Sako, Y., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.778399 · Cited by 13

Preclinical Assessment of MEK Inhibitors for Malignant Peripheral Nerve Sheath Tumors Reveals Differences in Efficacy and Adaptive Response

Gu, Y., Wang, W., Li, Y., Li, H., Guo, Z., Wei, C., Long, M., Chung, M., Aimaier, R., Li, Q., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.903177 · Cited by 13

A comprehensive overview of the molecular features and therapeutic targets in BRAF V600E ‐mutant colorectal cancer

Gu, R., Fang, H., Wang, R., Dai, W., & Cai, G. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1764 · Cited by 14

The complex journey of targeting RAS in oncology

Wasiak, K., Ciunowicz, D., Kierasińska, A., Węgierska, M., Pacholczyk, M., Rieske, P., & Stoczyńska-Fidelus, E. (2025) · BMC Cancer · doi:10.1186/s12885-025-14033-y · Cited by 14

Mutation-specific effects of NRAS oncogenes in colorectal cancer cells

Kuhn, N. R., Klinger, B., Uhlitz, F., Sieber, A., Rivera, M., Klotz‐Noack, K., Fichtner, I., Hoffmann, J., Blüthgen, N., Falk, C. S., et al. (2020) · Advances in Biological Regulation · doi:10.1016/j.jbior.2020.100778 · Cited by 13

Warburg Effect Revisited: Embodiment of Classical Biochemistry and Organic Chemistry. Current State and Prospects

Menchikov, L. G., Shestov, A. A., & Popov, A. V. (2023) · Biochemistry (Moscow) · doi:10.1134/s0006297923140018 · Cited by 12

Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Alfonso, P. G., García‐Foncillas, J., Salazar, R., Pérez‐Segura, P., García‐Carbonero, R., Musulén, E., Cuatrecasas, M., Landolfi, S., y Cajal, S. R., & Navarro, S. (2014) · Clinical & Translational Oncology · doi:10.1007/s12094-014-1252-0 · Cited by 12

A targeted genetic modifier screen in Drosophila uncovers vulnerabilities in a genetically complex model of colon cancer

Datta, I., Vassel, T., Linkous, B. K., Odum, T., Drew, C., Taylor, A., & Bangi, E. (2023) · G3 Genes Genomes Genetics · doi:10.1093/g3journal/jkad053 · Cited by 11

Fibroblast growth factor receptor 1 inhibition suppresses pancreatic cancer chemoresistance and chemotherapy-driven aggressiveness

Lin, Q., Serratore, A., Niu, J., Shen, S., Chaudhuri, T. R., Ma, W. W., Qu, J., Kandel, E., & Straubinger, R. M. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101064 · Cited by 12

Opportunities and Challenges of Small Molecule Inhibitors in Glioblastoma Treatment: Lessons Learned from Clinical Trials

Hoosemans, L., Vooijs, M., & Hoeben, A. (2024) · Cancers · doi:10.3390/cancers16173021 · Cited by 13

MEK and TAK1 Regulate Apoptosis in Colon Cancer Cells with KRAS-Dependent Activation of Proinflammatory Signaling

McNew, K. L., Whipple, W. J., Mehta, A. K., Grant, T. J., Ray, L. C., Kenny, C. J., & Singh, A. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0173 · Cited by 12

Effective personalized therapy for breast cancer based on predictions of cell signaling pathway activation from gene expression analysis

Jhan, J.-R., & Andrechek, E. R. (2017) · Oncogene · doi:10.1038/onc.2016.503 · Cited by 11

Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [18F] FDG-PET imaging combined with proteomic approaches

Tegnebratt, T., Ruge, E., Bader, S., Ishii, N., Aida, S., Yoshimura, Y., Ooi, C.-H., Lu, L., Mitsios, N., Méresse, V., et al. (2014) · EJNMMI Research · doi:10.1186/s13550-014-0034-6 · Cited by 11

Systems Modeling Identifies Divergent Receptor Tyrosine Kinase Reprogramming to MAPK Pathway Inhibition

Claas, A., Atta, L., Gordonov, S., Meyer, A. S., & Lauffenburger, D. A. (2018) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-018-0542-y · Cited by 11

Alpha-Enolase Protects Hepatocyte Against Heat Stress Through Focal Adhesion Kinase-Mediated Phosphatidylinositol 3-Kinase/Akt Pathway

Zeng, T., Cao, Y., Gu, T., Chen, L., Tian, Y., Li, G., Shen, J., Tao, Z., & Lu, L. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.693780 · Cited by 11

PI3K/AKT/mTOR Signaling Pathway Is Required for JCPyV Infection in Primary Astrocytes

Wilczek, M. P., Armstrong, F. J., Mayberry, C. L., King, B. L., & Maginnis, M. S. (2021) · Cells · doi:10.3390/cells10113218 · Cited by 11

Reduced expression of FRG1 facilitates breast cancer progression via GM-CSF/MEK-ERK axis by abating FRG1 mediated transcriptional repression of GM-CSF

Mukherjee, B., Tiwari, A. K., Palo, A., Pattnaik, N., Samantara, S. K., & Dixit, M. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01240-w · Cited by 11

Targeting the IκB Kinase Enhancer and Its Feedback Circuit in Pancreatic Cancer

Challa, S., Husain, K. M., Kim, R., Coppola, D., Batra, S. K., Cheng, J. Q., & Malafa, M. P. (2020) · Translational Oncology · doi:10.1016/j.tranon.2019.11.009 · Cited by 10

Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer

Ghosh, S., Fan, F., Powell, R. T., Roszik, J., Park, Y. S., STEPHAN, C. C., Sebastian, M. M., Tan, L., Sorokin, A. V., Lorenzi, P. L., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0110 · Cited by 10

KRAS G12V mutation-selective requirement for ACSS2 in colorectal adenoma formation

Budagyan, K., Cannon, A. C., Chatoff, A. G., Benton, D., Kurimchak, A., Araiza‐Olivera, D., Gerasimova, A., Snyder, N. W., Duncan, J. S., Uribe‐Alvarez, C., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115444 · Cited by 11

AS1041, a Novel Synthesized Derivative of Marine Natural Compound Aspergiolide A, Arrests Cell Cycle, Induces Apoptosis, and Inhibits ERK Activation in K562 Cells

Yuan, F., Qiao, L., Chen, Y., Qi, X., Liu, Y., Li, D., Gu, Q., Li, J., & Liu, M. (2017) · Marine Drugs · doi:10.3390/md15110346 · Cited by 10

Erdheim-Chester Disease

Maloku, E., & Loo, E. Y. (2020) · Advances in Molecular Pathology · doi:10.1016/j.yamp.2020.07.005 · Cited by 10

Modeling Adaptive Resistance of KRAS Mutant Colorectal Cancer to MAPK Pathway Inhibitors with a Three-Dimensional Tumor Model

Thakuri, P. S., Lamichhane, A., Singh, S. K., Gupta, M., Luker, G. D., & Tavana, H. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00115 · Cited by 11

Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations

Rittler, D., Molnár, E., Baranyi, M., Garay, T., Hegedüs, L., Aigner, C., Tóvári, J., Tı́már, J., & Hegedűs, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207649 · Cited by 11

Breast Cancer Subtypes and Prognosis: Answers to Subgroup Classification Questions, Identifying the Worst Subgroup in Our Single-Center Series

Coşar, R., Süt, N., Ozen, A., Tastekin, E., Topaloğlu, S., Çiçin, İ., Nurlu, D., Özler, T., Demir, S., Yıldız, G., et al. (2022) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s380754 · Cited by 10

Daidzein phosphorylates and activates 5-lipoxygenase via the MEK/ERK pathway: a mechanism for inducing the production of 5-lipoxygenase metabolite that inhibit influenza virus intracellular replication

Horio, Y., Isegawa, Y., & Shichiri, M. (2023) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2023.109276 · Cited by 10

Natural Anthraquinones as Promising MAPK3 Inhibitors for Complementary Cancer Therapy

Vaziri–Amjad, S., Moradi-Najmi, M., & Taherkhani, A. (2023) · Journal of Chemistry · doi:10.1155/2023/6683470 · Cited by 9

Concurrent inhibition of pBADS99 synergistically improves MEK inhibitor efficacy in KRASG12D-mutant pancreatic ductal adenocarcinoma

Tan, Y. Q., Sun, B., Zhang, X., Zhang, S., Guo, H., Basappa, B., Zhu, T., Sethi, G., Lobie, P. E., & Pandey, V. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06551-7 · Cited by 10

Emerging Landscape of Targeted Therapy of Breast Cancers With Low Human Epidermal Growth Factor Receptor 2 Protein Expression

Tozbikian, G. H., Krishnamurthy, S., Bui, M. M., Feldman, M. D., Hicks, D. G., Jaffer, S. M., Khoury, T., Wei, S., Wen, H. Y., & Pohlmann, P. R. (2023) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2022-0335-ra · Cited by 9

p70S6 kinase is a critical node that integrates HER-family and PI3 kinase signaling networks

Axelrod, M. J., Gordon, V. L., Mendez, R. E., Leimgruber, S., Conaway, M. R., Sharlow, E. R., Jameson, M. J., Gioeli, D. G., & Weber, M. J. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.03.013 · Cited by 10

High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma

Kohtamäki, L. M., Arjama, M., Mäkelä, S., Ianevski, P., Välimäki, K. E., Juteau, S., Ilmonen, S., Ungureanu, D., Kallioniemi, O., Murumägi, A., et al. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101290 · Cited by 8

A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors

Raimondi, V., Iannozzi, N. T., Burroughs-Garcìa, J., Toscani, D., Storti, P., & Giuliani, N. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00095 · Cited by 8

Chitosan Oligosaccharide Promotes Junction Barrier through Modulation of PI3K/AKT and ERK Signaling Intricate Interplay in T84 Cells

Mehmood, T., Pichyangkura, R., & Muanprasat, C. (2023) · Polymers · doi:10.3390/polym15071681 · Cited by 8

Functional genomic characterization of a synthetic anti-HER3 antibody reveals a role for ubiquitination by RNF41 in the anti-proliferative response

Turowec, J. P., Lau, E. W. T., Wang, X., Brown, K. R., Fellouse, F. A., Jawanda, K. K., Pan, J., Moffat, J., & Sidhu, S. S. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004420 · Cited by 8

Binimetinib, a novel MEK1/2 inhibitor, exerts anti-leukemic effects under inactive status of PI3Kinase/Akt pathway

Sakakibara, K., Tsujioka, T., Kida, J., Kurozumi, N., Nakahara, T., Suemori, S.-I., Kitanaka, A., Arao, Y., & Tohyama, K. (2019) · International Journal of Hematology · doi:10.1007/s12185-019-02667-1 · Cited by 8

Rapamycin synergizes the cytotoxic effects of MEK inhibitor binimetinib and overcomes acquired resistance to therapy in melanoma cell lines in vitro

Ryabaya, O. O., Abramov, I. S., Khochenkov, D. A., Akasov, R., Sholina, N. V., & Prokofieva, A. A. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01089-3 · Cited by 10

Inhibiting BRAF/EGFR/MEK suppresses cancer stemness and drug resistance of primary colorectal cancer cells

Lamichhane, A., Luker, G. D., Agarwal, S., & Tavana, H. (2023) · Oncotarget · doi:10.18632/oncotarget.28517 · Cited by 7

Metabolic and Regulatory Pathways Involved in the Anticancer Activity of Perillyl Alcohol: A Scoping Review of In Vitro Studies

Brochado, A. C. B., de Moraes, J. A., de Oliveira, B. R., Lima, V. H. D. S., Mariano, E. D., Karande, S., Romasco, T., Leite, P. E. C., Mourão, C. F., & Alves, G. G. (2024) · Cancers · doi:10.3390/cancers16234003 · Cited by 8

Targeting Mechanisms of Resistance to Anti-EGF Receptor Therapy in KRAS Wild-Type Colorectal Cancer: The Path to More Personalized Medicine

Fakih, M. (2013) · Future Oncology · doi:10.2217/fon.12.204 · Cited by 6

Translating Genomic Profiling to Gastrointestinal Cancer Treatment

Harada, K., Kaya, D. M., Shimodaira, Y., Song, S., Baba, H., & Ajani, J. A. (2017) · Future Oncology · doi:10.2217/fon-2016-0422 · Cited by 7

An ultrasensitive fiveplex activity assay for cellular kinases

Smolko, C. M., & Janes, K. A. (2019) · Scientific Reports · doi:10.1038/s41598-019-55998-8 · Cited by 7

Concurrent inhibition of ErbB family and MEK/ERK kinases to suppress non-small cell lung cancer proliferation.

Lin, X., Liao, J., Geng, X., Dan, H., & Chen, L. (2020) · PubMed Central · Cited by 7

KRAS mutations in metastatic colorectal cancer: from a de facto ban on anti-EGFR treatment in the past to a potential biomarker for precision medicine

Coupez, D., Hulo, P., Touchefeu, Y., Denis, M. G., & Bennouna, J. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1967318 · Cited by 8

Predictive biomarkers for response to trametinib in non-small cell lung cancer

Parekh, P. R., Botting, G. M., Thurber, D. B., Boruszczak, M., Murphy, W., & Bertenshaw, G. P. (2022) · Tumor Biology · doi:10.3233/tub-220009 · Cited by 7

Phosphoproteome analysis of the MAPK pathway reveals previously undetected feedback mechanisms

Gnad, F., Doll, S., Song, K. W., Stokes, M. P., Moffat, J. G., Liu, B., Arnott, D. P., Wallin, J. J., Friedman, L. S., Hatzivassiliou, G., et al. (2016) · PROTEOMICS · doi:10.1002/pmic.201600119 · Cited by 7

Negative feedback regulation of ErbB4 tyrosine kinase activity by ERK-mediated non-canonical phosphorylation

Haryuni, R. D., Watabe, S., Yamaguchi, A., Fukushi, Y., Tanaka, T., Kawasaki, Y., Zhou, Y., Yokoyama, S., & Sakurai, H. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.04.125 · Cited by 8

Unlocking the Molecular Targets in Non-Small-Cell Lung Cancer and a Nanomedicine-Based Remedy

Sarma, K., Akhter, M. H., Alalmaie, A., Ahmad, I., Ansari, M. N., Khalilullah, H., Farhana, S. A., Hussain, S. M., & Aljadaan, A. M. (2025) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2024053289 · Cited by 6

HER3 in breast cancer: molecular insights, clinical implications, and therapeutic horizons

Ergün, Y. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2540355 · Cited by 6

Wild-type RAS signaling is an essential therapeutic target in RAS -mutated cancers

Sealover, N. E., Finniff, B. A., Hughes, J. M., Sheffels, E., Lee, H., LaMorte, J. P., Gambhir, V., Beckley, Z., Linke, A. J., Wilkerson, M. D., et al. (2025) · Science Signaling · doi:10.1126/scisignal.adx5186 · Cited by 7

Targeted therapy sensitivity and resistance in solid malignancies

Jokinen, E. (2014) · Cited by 6

Activity-Based Proteomics Reveals Heterogeneous Kinome and ATP-Binding Proteome Responses to MEK Inhibition in KRAS Mutant Lung Cancer

Kim, J., Stewart, P. A., Borne, A. L., Fang, B., Welsh, E. A., Chen, Y. A., Eschrich, S. A., Koomen, J. M., & Haura, E. B. (2016) · Proteomes · doi:10.3390/proteomes4020016 · Cited by 6

A comprehensive review of targeting RAF kinase in cancer

Hossain, M. A. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177142 · Cited by 6

Targeting SHP2 sensitizes differentiated thyroid carcinoma to the MEK inhibitor.

Zhi, J., Yi, J., Hou, X., Wang, W., Yang, W., Hu, L., Huang, J., Guo, S., Ruan, X., Gao, M., et al. (2022) · PubMed Central · Cited by 6

Dual targeting of melanoma translation by MNK/eIF4E and PI3K/mTOR inhibitors

Gil, D., Zarzycka, M., Pabijan, J., Lekka, M., & Dulińska-Litewka, J. (2023) · Cellular Signalling · doi:10.1016/j.cellsig.2023.110742 · Cited by 6

Approaches for measuring signalling plasticity in the context of resistance to targeted cancer therapies

Wilkes, E. H., Casado, P., & Cutillas, P. R. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140029 · Cited by 6

Exosomal miRNAs as Novel Pharmacodynamic Biomarkers for Cancer Chemopreventive Agent Early Stage Treatments in Chemically Induced Mouse Model of Lung Squamous Cell Carcinoma

Zhou, Y., Zhang, Q., Du, M., Xiong, D., Wang, Y., Mohammed, A., Lubet, R. A., Wang, L., & You, M. (2019) · Cancers · doi:10.3390/cancers11040477 · Cited by 6

Evaluation of the RAS signaling network in response to MEK inhibition using organoids derived from a familial adenomatous polyposis patient

Osumi, H., Muroi, A., Sakahara, M., Kawachi, H., Okamoto, T., Natsume, Y., Yamanaka, H., Takano, H., Kusama, D., Shinozaki, E., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-74530-x · Cited by 6

An evaluation of buparlisib for the treatment of head and neck squamous cell carcinoma

Lenze, N. R., Chera, B. S., & Sheth, S. H. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1825684 · Cited by 6

GANT61/BI-847325 combination: a new hope in lung cancer treatment

El-Kishky, A. H. M., Moussa, N., Helmy, M. W., & Haroun, M. (2022) · Medical Oncology · doi:10.1007/s12032-022-01738-4 · Cited by 6

An Overview Regarding Pharmacogenomics and Biomarkers Discovery: Focus on Breast Cancer

Scandolara, T. B., Pires, B. R. B., Vacario, B. G. L., de Amorim, Í. S. S., Siqueira, P. B., Serpeloni, J. M., Mencalha, A. L., Bonvicino, C. R., & Panis, C. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026622666220801115040 · Cited by 6

bioPROTACs establish RAS as a degradable target and provide novel RAS biology insightsPreprint

Lim, S., Khoo, R., Juang, Y.-C. A., Gopal, P., Zhang, H., Yeo, C., Peh, K. M., Teo, J., Ng, S., Henry, B., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.26.174565 · Cited by 6

Multiscale Modeling of Tumor-Macrophage Interactions Underlying Immunotherapy Resistance in Glioblastoma

Lin, H., Zhang, J., Nie, Q., & Sun, X. (2025) · Multiscale Modeling and Simulation · doi:10.1137/24m1663077 · Cited by 5

Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling

Li, D., Miermont, A. M., Sable, R. V., Quadri, H. S., Griner, L. A. M., Martin, S. E., Odzorig, T., De, S., Ferrer, M., Powers, A. S., et al. (2023) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-1036 · Cited by 5

Chronic Kidney Disease–associated Lung Injury Is Mediated by Phosphate-induced MAPK/AKT Signaling

Bollenbecker, S., Hirsch, M. J., Matthews, E. L., Easter, M., Vang, S., Howze, P. H., Morales, A. N., Harris, E. S., Barnes, J. W., Faul, C., et al. (2024) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2024-0008oc · Cited by 5

A Phase I Clinical Trial of Trametinib in Combination with TAS-102 in Patients with Chemotherapy-Resistant RAS-Mutated (PIK3CA/PTEN-Wild Type) Metastatic Colorectal Cancer

Chuang, J., Gong, J., Li, S. M., Wang, C., & Fakih, M. (2022) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2022.05.004 · Cited by 6

Ocular Toxicity Profile of ST-162 and ST-168 as Novel Bifunctional MEK/PI3K Inhibitors

Smith, A. J. H., Pawar, M. D., Dort, M. E. V., Galbán, S., Welton, A. R., Thurber, G. M., Ross, B. D., & Besirli, C. G. (2018) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2017.0126 · Cited by 5

ErbB Receptors as Prognostic and Therapeutic Drug Targets in Bone and Soft Tissue Sarcomas

Wang, H., Yang, Q., Fu, Z., Zuo, D., Hua, Y., & Cai, Z. (2014) · Cancer Investigation · doi:10.3109/07357907.2014.964409 · Cited by 5

Learning Single-Cell Perturbation Responses using Neural Optimal TransportPreprint

Bunne, C., Stark, S. G., Gut, G., del Castillo, J. S., Levesque, M. P., Lehmann, K.-V., Pelkmans, L., Krause, A., Rätsch, G., & * (2022) · Research Square · doi:10.21203/rs.3.rs-1805107/v1 · Cited by 5

Erk1R84H is an oncoprotein that causes hepatocellular carcinoma in mice and imposes a rigorous negative feedback loop

Soudah, N., Baskin, A., Darash‐Yahana, M., Darlyuk‐Saadon, I., Smorodinsky-Atias, K., Shalit, T., Yu, W., Savidor, A., Pikarsky, E., & Engelberg, D. (2025) · Oncogene · doi:10.1038/s41388-025-03437-6 · Cited by 4

Astragaloside IV delayed the epithelial–mesenchymal transition in peritoneal fibrosis by inhibiting the activation of EGFR and PI3K-AKT pathways

Huang, Y., Chu, C., Qiu, W.-H., Chen, J., Cao, L.-X., Ji, S.-Y., Zhu, B., Wang, G., & Shen, Q. (2025) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2025.09.001 · Cited by 4

Combining mechanistic quantitative systems pharmacology modeling and patient-derived organoid testing in MET-aberrant non-small cell lung cancer for high-throughput combination efficacy analysis and personalized treatment design

Hu, J., Zhao, Y., Rao, Q., Li, G., Jiao, Z., Wang, H., Qu, Y., Xu, S., Gu, Z., Wang, T., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1685468 · Cited by 4

Developments of MEK inhibitors as future cancer therapies: what have we learned from preclinical and clinical studies?

Petrini, I., & Giaccone, G. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2599455 · Cited by 4

Targeting MEK in cancer and beyond: mechanistic insights and therapeutic opportunities

Chan, W. Y., da Silva, I. P., Long, G. V., & Rizos, H. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00199-6 · Cited by 5

p38 mitogen-activated protein kinase inhibitors

El‐Damasy, A. K., Salem, M. S. H., Sebaiy, M. M., & Elgawish, M. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-96121-9.00011-5 · Cited by 4

Robust anti-myeloma effect of TAS0612, an RSK/AKT/S6K inhibitor, with venetoclax regardless of cytogenetic abnormalities

Okamoto, H., Mizutani, S., Tsukamoto, T., Katsuragawa‐Taminishi, Y., Kawaji‐Kanayama, Y., Mizuhara, K., Muramatsu, A., Isa, R., Fujino, T., Shimura, Y., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02439-9 · Cited by 5

SAR Probing of KX2-391 Provided Analogues With Juxtaposed Activity Profile Against Major Oncogenic Kinases

Omar, A. M., Khayat, M. T. A., Ahmed, F., Muhammad, Y. A., Malebari, A. M., Ibrahim, S. M., Khan, M. I., Shah, D. K., Childers, W. E., & El‐Araby, M. E. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.879457 · Cited by 4

Review on EGFR-ERK1/2 signaling cascade: implications on cell proliferation in health and disease

Fetoh, M. E. A., Abdel‐Fattah, M. M., Afify, H., Ramadan, L. A. A., & Mohamed, W. R. (2023) · Egyptian Pharmaceutical Journal · doi:10.4103/epj.epj_52_23 · Cited by 4

Oncogenic KRAS addiction states differentially influence MTH1 expression and 8-oxodGTPase activity in lung adenocarcinoma

Mateo-Victoriano, B., Samaranayake, G. J., Pokharel, S. P., Sahayanathan, G. J., Jayaraj, C. J., Troccoli, C. I., Watson, D. C., Mohsen, M. G., Guo, Y., Kool, E. T., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103610 · Cited by 4

Volatilomic response to targeted cancer therapy in vitro

Leung, K., Kim, I., Das, B., & Hanna, G. B. (2025) · Scientific Reports · doi:10.1038/s41598-025-04886-5 · Cited by 3

Focal adhesion kinase: A promising regulator of colitis-associated healing

Malek, K. K., Kumar, B., Ahmad, R., Singh, A. B., & Basson, M. D. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i33.105466 · Cited by 3

Harnessing transcriptomics for discovery of natural products to overcome acquired cancer resistance

Yeo, H., Kim, S.-Y., & Park, S. (2025) · Archives of Pharmacal Research · doi:10.1007/s12272-025-01590-w · Cited by 4

Targeting RAS–RAF–MEK–ERK signaling in mucinous ovarian cancer: a translational evidence synthesis and clinical framework

Bartl, T., & Castillo‐Tong, D. C. (2026) · International Journal of Gynecological Cancer · doi:10.1016/j.ijgc.2026.104485 · Cited by 3

Phosphatidylinositol-3-Kinase (PI3K) and Histone Deacetylase (HDAC) Multitarget Inhibitors: An Update on Clinical and Preclinical Candidates

Lima, A. D. S., & Lima, L. M. (2026) · Pharmaceuticals · doi:10.3390/ph19010130 · Cited by 4

Targeting Non-V600 Mutations in BRAF: A Single Institution Retrospective Analysis and Review of the Literature

Chaudhary, H. A., Cannon, T. L., & Winer, A. (2024) · Drugs in R&D · doi:10.1007/s40268-024-00475-5 · Cited by 3

New Targets for Therapy in Lung Cancer

Mansfield, A. S., Dy, G. K., Ahn, M.-J., & Adjei, A. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-52357-8.00048-2 · Cited by 2

Novel compound ZCJ14, a gefitinib analog, exhibited prominent anti-cancer effect among several cancer cell lines

Wang, J., Yan, P., Wang, H., Zuo, S., Zhang, S., Cao, Y.-X., & Cao, L. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120875 · Cited by 3

Progress of research and development of MAPK pathway inhibitors

Ishii, N. (2013) · Folia Pharmacologica Japonica · doi:10.1254/fpj.141.15 · Cited by 3

Formal Methods for Biological Systems: Languages, Algorithms, and Applications

Wang, Q. (2016) · Cited by 3

Abstract 5632: MEK inhibition leads to elevated HER3:PI3K in EGFR or HER2 driven cancer through feedback induction of HER1:3 and HER2:3 dimers.

Hoe, N., Mateling, M., Ma, Y., Jin, K., Zhou, J., Kirkland, R. E., Kuy, C., Liu, X., Kim, P., & Singh, S. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-5632

MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK ‐mediated HER 2 phosphorylation at Thr701

Chen, C., Hsia, T., Yeh, M., Chen, T.-H., Chen, Y., Chen, J., Wei, Y., Tu, C., & Huang, W. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12102 · Cited by 65

Abstract 2321: Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS signaling.

Will, M., Toy, W., Yao, Z., Poulikakos, P. I., Rodrik-Outmezguine, V. S., Schneider, C., Paul, J., Baselga, J. M., Liu, N., Rosen, N. X., et al. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-2321

The crossregulation between ERK and PI3K signaling pathways determines the tumoricidal efficacy of MEK inhibitor

Won, J., Yang, H. W., Shin, S., Lee, J., Heo, W. D., & Cho, K. (2012) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjs021 · Cited by 75

Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells

Yuen, H., Abramczyk, O., Montgomery, G. W., Chan, K.-K., Huang, Y., Sasazuki, T., Shirasawa, S., Gopesh, S., Chan, K.-W., Fennell, D. A., et al. (2012) · Bioscience Reports · doi:10.1042/bsr20120050 · Cited by 33